TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

Mdxhealth announced a collaboration with the University of Oxford to initiate Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial, the world's largest randomized clinical trial for localized prostate cancer treatment. This study aims to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, potentially impacting clinical practice guidelines and payer coverage.

Insights
TSLA   negative

Thiel dramatically reduced his Tesla holdings from 272,613 to 65,000 shares, indicating reduced confidence


MDXH   positive

The company is advancing its GPS test through validation in the world's largest randomized prostate cancer trial, which could establish clinical credibility, influence treatment guidelines, and expand payer coverage. This represents significant progress in precision diagnostics and market positioning.